Basic Information
SYMVENU HARD CAPSULES 6MG
CAPSULE, GELATIN COATED
Regulatory Information
SIN15746P
July 11, 2019
Prescription Only
Therapeutic
ORAL
August 10, 2023
May 30, 2025
XN05AX15
Company Information
MITSUBISHI TANABE PHARMA SINGAPORE PTE. LTD.
MITSUBISHI TANABE PHARMA SINGAPORE PTE. LTD.
Active Ingredients
Strength: 6.000mg
Detailed Information
Contraindications
**3.3 Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in section 5.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. Concomitant administration of strong or moderate CYP3A4 inhibitors (see section 3.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Concomitant administration of strong or moderate CYP3A4 inducers (see section 3.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**3.1 Therapeutic indications** Symvenu® is indicated for - treatment of schizophrenia in adult patients, - acute treatment of manic or mixed episodes associated with bipolar I disorder in adult patients, - treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adult patients.